Olorofim in Treatment of Patients With Poorly Controlled Disseminated Coccidioidomycosis: A Single-Group, Open-Label, Phase 2b, Multicenter Study: Annals of Internal Medicine: Vol 0, No 0 https://t.co/8erxjyrflx
Instead of watching an hour of Netflix, watch this 2-hour Stanford lecture, which will teach you more about how LLMs like ChatGPT and Claude are built than most people working at top AI companies learn in their entire careers.
Olorofim in Treatment of Patients With Poorly Controlled Disseminated Coccidioidomycosis: A Single-Group, Open-Label, Phase 2b, Multicenter Study: Annals of Internal Medicine: Vol 0, No 0 https://t.co/M90C1qlVmB
Great case report publication by this team: Extrathoracic coccidioidomycosis presenting as acute appendicitis https://t.co/KZhUmfjB9S
@drgcorella11@docshikham
@MBrigmon Less relapse, however, consider the harm caused by treatment delay due to exorbitant cost and insurance non-coverage with fidax requiring Rx change back to vanco
Congratulations to our ID fellow Dr. Shikha Mishra for winning best poster at the 68th annual Cocci Study Group meeting! @ID_fellows@VFI_Research @KernMedicalim